TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1491124

Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg and 1,000 mg daily (administered in three divided doses)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (CE) 0.625 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 4037631

Group type: EXPERIMENTAL
Intervention: 10% aqueous solution of povidone-iodine (Betadine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 45
Study: 31394921

Group type: EXPERIMENTAL
Intervention: Ripple mapping (RM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Local activation time (LAT) mapping
Number of subjects: 83

Group type: COMPARATOR
Intervention: Local activation time (LAT) mapping after crossover to RM
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ripple mapping (RM) after crossover to LAT
Number of subjects: 83
Study: 29973314

Group type: EXPERIMENTAL
Intervention: Lifetime mental illness (LMI) including depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifetime mental illness (LMI) including 2+ LMIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifetime mental illness (LMI) including 2+ LMIs with depression
Number of subjects: 0

Group type: COMPARATOR
Intervention: No history of LMI
Number of subjects: 0
Study: 27307270

Group type: EXPERIMENTAL
Intervention: 3D computer module (n=49)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Written text (n=51)
Number of subjects: 100
Study: 23812581

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: King Vision with channeled blade (KVC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: King Vision with non‐channeled blade (KVNC)
Number of subjects: 31
Study: 21859743

Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 19901117

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: Dose-dense epirubicin and cyclophosphamide followed by Paclitaxel (EC/T)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: Doxorubicin and cyclophosphamide followed by Paclitaxel (AC/T)
Number of subjects: 2104

Group type: COMPARATOR
Intervention: AC/T versus CEF
Number of subjects: 2104

Group type: COMPARATOR
Intervention: AC/T versus EC/T
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: EC/T versus CEF
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: CEF
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: EC/T
Number of subjects: 2104

Group type: COMPARATOR
Intervention: AC/T
Number of subjects: 2104

Group type: EXPERIMENTAL
Intervention: EC/T and CEF
Number of subjects: 2104
Study: 17395048

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 12

Group type: COMPARATOR
Intervention: No pacing
Number of subjects: 12
Study: 16136469

Group type: EXPERIMENTAL
Intervention: High-dose vCP1452 (10^8.0 TCID50)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Regular-dose vCP1452 (10^7.26 TCID50)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 110
Study: 12186798

Group type: EXPERIMENTAL
Intervention: 4-week endurance training
Number of subjects: 95

Group type: COMPARATOR
Intervention: No training
Number of subjects: 95
Study: 10197379

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 2367

Group type: COMPARATOR
Intervention: Placebo or no prophylaxis
Number of subjects: 2367
Study: 7776501

Group type: EXPERIMENTAL
Intervention: Supplementary vitamin E intake of 100 IU per day or greater
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Supplementary vitamin E intake within the drug group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Supplementary vitamin E intake within the placebo group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Supplementary vitamin C intake
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Increased dietary intake of vitamin E or vitamin C
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Use of multivitamins
Number of subjects: 156
Study: 2336314

Group type: COMPARATOR
Intervention: No needle changes
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 1 needle change
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 2 needle changes
Number of subjects: 303
Study: 111945

Group type: EXPERIMENTAL
Intervention: 25 g of glucose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 25 g of xylose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 g of sodium chloride
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nasal administration of small amounts of vasopressin
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 g of sodium chloride with beef-meal
Number of subjects: 6
Study: 31879124

Group type: EXPERIMENTAL
Intervention: Booster Immunization group (BI) - received a single dose of OCV after 3 years
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo group (Primary Immunization group: PI) - did not receive a booster dose
Number of subjects: 240
Study: 31651318

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Surgery (CAS)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional (manual implantation)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups (CAS and Conventional)
Number of subjects: 122
Study: 28950855

Group type: EXPERIMENTAL
Intervention: Repeated testing
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no repeated testing)
Number of subjects: 114
Study: 25667135

Group type: EXPERIMENTAL
Intervention: Ethanol celiac plexus neurolysis (50% ethanol)
Number of subjects: 485

Group type: COMPARATOR
Intervention: 0.9% normal saline placebo control
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Surgical resection of malignancy
Number of subjects: 485
Study: 23376896

Group type: EXPERIMENTAL
Intervention: Biofinity multifocal (MF) contact lens
Number of subjects: 20

Group type: COMPARATOR
Intervention: Biofinity monovision (MV) contact lens
Number of subjects: 20
Study: 21508745

Group type: EXPERIMENTAL
Intervention: Moderate fish consumption (three servings per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fish consumption less than once a month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fish consumption more often than less than once a month
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythrocyte omega-3 levels
Number of subjects: 0
Study: 19637104

Group type: EXPERIMENTAL
Intervention: Zonisamide 100 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18041300

Group type: EXPERIMENTAL
Intervention: Influenza vaccination (VAXIGRIP(R) 2003 Southern hemisphere formulation)
Number of subjects: 527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study: 14713376

Group type: EXPERIMENTAL
Intervention: Performance-avoidance goal
Number of subjects: 75

Group type: COMPARATOR
Intervention: Performance-approach goal
Number of subjects: 75

Group type: COMPARATOR
Intervention: Mastery goal
Number of subjects: 75
Study: 10601064

Group type: EXPERIMENTAL
Intervention: Magnetic resonance cholangiography (MRC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiography (ERC)
Number of subjects: 20
Study: 9176005

Group type: EXPERIMENTAL
Intervention: Epineural ligatures
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Epineural flaps
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Epineural grafts
Number of subjects: 23
Study: 1497476

Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulation (VT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Erotic video (VID)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined vibrotactile and erotic video stimulation (VID+VT)
Number of subjects: 34
Study: 3545931

Group type: EXPERIMENTAL
Intervention: Combined insulin plus sulfonylurea (gliclazide 40 to 240 mg daily for 12 months)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Insulin treatment only (control group)
Number of subjects: 30
Study: 31470175

Group type: EXPERIMENTAL
Intervention: Curcumin (3 g/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 30850455

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis (AD)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Moisturizers with high water: oil ratios (ie, lotions)
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Moisturizers with low water:oil content (ie, ointments)
Number of subjects: 652
Study: 29263340

Group type: EXPERIMENTAL
Intervention: Stroboscopic vision
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal vision
Number of subjects: 20
Study: 24874588

Group type: EXPERIMENTAL
Intervention: Surfactant-containing saline solution (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline without surfactant (group 2)
Number of subjects: 40
Study: 23862298

Group type: EXPERIMENTAL
Intervention: Eye health education program (InCHARGE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social-contact control presentation
Number of subjects: 0
Study: 21916358

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gel (CG)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine spray (CS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo gel (PG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo spray (PS)
Number of subjects: 29
Study: 19543665

Group type: EXPERIMENTAL
Intervention: Non-centralization
Number of subjects: 331

Group type: COMPARATOR
Intervention: Centralization
Number of subjects: 331
Study: 16428906

Group type: EXPERIMENTAL
Intervention: Concurrent myofeedback (feedback provided immediately during the trial)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Terminal myofeedback (feedback provided delayed after the trial)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No myofeedback
Number of subjects: 32
Study: 15207760

Group type: EXPERIMENTAL
Intervention: Cyclic therapy with etidronate (CTE) - 400 mg/day oral etidronate for 2 weeks followed by 12 weeks of 500 mg/day calcium lactate, repeated every 14 weeks (early-etidronate group)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cyclic therapy with etidronate (CTE) - initiated after 18 months of no treatment (late-etidronate group)
Number of subjects: 55

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 55
Study: 11152831

Group type: EXPERIMENTAL
Intervention: MULTI-LINK (ML) stent
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Palmaz-Schatz (PS) stent
Number of subjects: 1040
Study: 9652995

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate, 300 mg, intramuscularly every 3 weeks for 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 51
Study: 8158680

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A, n = 118)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Initial chemotherapy (cisplatin and infusional fluorouracil) followed by loco-regional treatment (group A)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Loco-regional treatment alone (group B, n = 119)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Loco-regional treatment alone (group B)
Number of subjects: 237
Study: 3045792

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 10-15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (IM) 50 mg and 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (IM) 50 mg and 100 mg + Diazepam (DZ) 10-15 mg
Number of subjects: 0
Study: 30212845

Group type: EXPERIMENTAL
Intervention: Open-label placebo (two placebo tablets twice a day for 10 days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 70
Study: 27760533

Group type: EXPERIMENTAL
Intervention: TOBY therapy + therapy as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: therapy as usual
Number of subjects: 0
Study: 24712684

Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual physical activity
Number of subjects: 170
Study: 23001704

Group type: EXPERIMENTAL
Intervention: Boceprevir 800 mg every 8 hours for 9 days plus a single dose of raltegravir 400 mg on day 10
Number of subjects: 24

Group type: COMPARATOR
Intervention: Raltegravir 400 mg alone
Number of subjects: 24
Study: 21953611

Group type: EXPERIMENTAL
Intervention: T1DM with hyperglycemia
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: T1DM with severe hypoglycemia
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nondiabetic control (NDC) siblings
Number of subjects: 75
Study: 19367153

Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine capsules (ERCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release carbamazepine (IR)
Number of subjects: 0
Study: 16995864

Group type: EXPERIMENTAL
Intervention: 25 mg BIW etanercept for 24 weeks (Study 1)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 25 mg BIW etanercept for 12 weeks (Study 2)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 50 mg BIW etanercept for 12 weeks (Study 2)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 25 mg QW etanercept for 24 weeks (Study 3)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 25 mg BIW etanercept for 24 weeks (Study 3)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: 50 mg BIW etanercept for 24 weeks (Study 3)
Number of subjects: 1300
Study: 15327681

Group type: EXPERIMENTAL
Intervention: EBM intervention
Number of subjects: 39
Study: 11526374

Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg IV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9574353

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 71

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 71
Study: 8489976

Group type: EXPERIMENTAL
Intervention: Intrathecal catheter kept in place for 12 to 24 hours (group 2)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Intrathecal catheter immediately withdrawn (group 1)
Number of subjects: 87
Study: 3284830

Group type: EXPERIMENTAL
Intervention: carbocysteine-sobrerol combination
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 29561181

Group type: COMPARATOR
Intervention: Regular day shift (8 h on duty)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Continuous day-night shift (24 h on duty)
Number of subjects: 34
Study: 28215346

Group type: EXPERIMENTAL
Intervention: HyFlex EDM (HFEDM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: ProTaper Next (PTN)
Number of subjects: 40
Study: 26233732

Group type: EXPERIMENTAL
Intervention: Febuxostat 40mg once daily for 6 months
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 23438800

Group type: EXPERIMENTAL
Intervention: Interscalene group (IG) received 30 mL of 0.33% levobupivacaine with adrenalin 1:200,000.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Selective group (SG) received 15 mL of 0.33% levobupivacaine on each nerve (suprascapular and axillary).
Number of subjects: 68

Group type: COMPARATOR
Intervention: Selective group (SG)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Interscalene group (IG) and Selective group (SG)
Number of subjects: 68
Study: 16823591

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Balanced amino acid drink (control)
Number of subjects: 10
Study: 12542554

Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 injection treatment
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 10213011

Group type: EXPERIMENTAL
Intervention: Irinotecan 350 mg/m2
Number of subjects: 2

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 2

Group type: COMPARATOR
Intervention: Best estimated infusional 5‐FU
Number of subjects: 2
Study: 7587606

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Anticoagulant therapy
Number of subjects: 30
Study: 1980200

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7428803

Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ampicillin (500 mg)
Number of subjects: 0
Study: 29030086

Group type: EXPERIMENTAL
Intervention: Ceramic plates
Number of subjects: 6326

Group type: COMPARATOR
Intervention: Disposable plates
Number of subjects: 6326

Group type: EXPERIMENTAL
Intervention: Oblong/rectangular plates
Number of subjects: 6326

Group type: COMPARATOR
Intervention: Other plate types (colour and sectioning)
Number of subjects: 6326
Study: 26963188

Group type: EXPERIMENTAL
Intervention: ERASE-Stress intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Managing Emergencies and Traumatic Incidents (METI) program
Number of subjects: 63
Study: 25548079

Group type: EXPERIMENTAL
Intervention: 3 weekly intra‐articular injections of hyaluronic acid (HA)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 196
Study: 23950640

Group type: EXPERIMENTAL
Intervention: Thai dance group
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 20936975

Group type: EXPERIMENTAL
Intervention: 40 mg laninamivir octanoate
Number of subjects: 1003

Group type: EXPERIMENTAL
Intervention: 20 mg laninamivir octanoate
Number of subjects: 1003

Group type: COMPARATOR
Intervention: oseltamivir (75 mg, administered orally twice daily for 5 days)
Number of subjects: 1003
Study: 18779299

Group type: EXPERIMENTAL
Intervention: Flax oil (2.4 g/d)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Flax oil (3.6 g/d)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fish oil (0.6 g/d)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fish oil (1.2 g/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sunflower oil (1 g/d)
Number of subjects: 62
Study: 15950716

Group type: EXPERIMENTAL
Intervention: Brief pain-management programme
Number of subjects: 402

Group type: COMPARATOR
Intervention: Manual therapy
Number of subjects: 402
Study: 12608555

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 11
Study: 10703122

Group type: EXPERIMENTAL
Intervention: Benign melanocytic proliferations (Group 1); kappa statistic (k) = 0.76
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Malignant melanocytic proliferations (Group 2); kappa statistic (k) = 0.70
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Indeterminate melanocytic proliferations (Group 3); kappa statistic (k) = -0.045
Number of subjects: 15
Study: 7477800

Group type: EXPERIMENTAL
Intervention: Combined cognitive‐behavioral therapy, nutritional counselling and antidepressant drugs (nortriptyline for 7, fluoxetine for 15)
Number of subjects: 22
Study: 1953053

Group type: EXPERIMENTAL
Intervention: Lamicel tent
Number of subjects: 108

Group type: COMPARATOR
Intervention: Cervagem (1 mg gemeprost pessary)
Number of subjects: 108
Study: 6908909

Group type: EXPERIMENTAL
Intervention: Structured teaching about essential hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no structured teaching)
Number of subjects: 0
Study: 30872375

Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30 mg THC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 28506339

Group type: EXPERIMENTAL
Intervention: AR group with intervention (n=22)
Number of subjects: 96

Group type: COMPARATOR
Intervention: AR group without intervention (n=22)
Number of subjects: 96

Group type: COMPARATOR
Intervention: AR group (n=44) and non-AR group (n=20)
Number of subjects: 96
Study: 25391252

Group type: EXPERIMENTAL
Intervention: 150 mg/day Pycnogenol®
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 93
Study: 23392474

Group type: EXPERIMENTAL
Intervention: Learning a new piece of music
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 21276217

Group type: EXPERIMENTAL
Intervention: Educational program for primary prevention of WMSD (six consecutive weekly sessions)
Number of subjects: 101

Group type: COMPARATOR
Intervention: General health education (identical schedule to intervention group)
Number of subjects: 101
Study: 19550287

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal gel (0.001, 0.002, 0.005, or 0.02%)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal gel (0.02%)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal gel
Number of subjects: 119
Study: 17761367

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg)
Number of subjects: 13
Study: 15489632

Group type: EXPERIMENTAL
Intervention: Sustained hypotension (all ED SBP <100 mmHg for > or =60 min)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Lowest ED systolic blood pressure (SBP)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Sustained hypotension
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for signs and symptoms of shock
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: In-hospital mortality rate
Number of subjects: 190
Study: 11431597

Group type: EXPERIMENTAL
Intervention: Programmable insulin pump
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-programmable insulin pump
Number of subjects: 10
Study: 9685793

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Naclof)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 64
Study: 8090301

Group type: COMPARATOR
Intervention: Flunitrazepam 2 mg (group F)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Trazodone 50 mg (group T)
Number of subjects: 86